Kv10.1 is not only expressed in the primary tumours, but also in brain metastases, where it might contribute to tumour progression, because patients with brain metastases and moderate Kv10.1 expression showed improved survival when treated with different Kv10.1-blocking antidepressants (Martinez et al. 2015) compared with those treated with other antidepressant drugs. Here, KCNH1 is linked to neoplasm.